- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07572890
Adia Med of Winter Park LLC Chronic Kidney Disease Research Study
16 juni 2026 bijgewerkt door: Adia Med of Winter Park LLC
The goal of this clinical trial is to learn whether a new regenerative treatment called AdiaVita, made from umbilical cord blood-derived stem cells and exosomes combined with glutathione, is safe and can help improve kidney function in adults with chronic kidney disease (CKD).
In this condition, the kidneys gradually lose their ability to filter blood as well as they should.
The main questions it aims to answer are whether AdiaVita plus glutathione improves kidney function better than control treatments, as measured by blood tests for estimated glomerular filtration rate (eGFR) and creatinine levels, and whether the treatment is safe with acceptable side effects.
Researchers will compare three groups.
One group will receive AdiaVita plus glutathione.
A second group will receive glutathione plus a placebo for AdiaVita.
The third group will receive placebos for both treatments.
A placebo looks like the real treatment but contains no active ingredients.
This will help determine if the full treatment works better than the controls.
Approximately 100 adults aged 18 to 80 with stage 2 to 4 chronic kidney disease may participate.
Participants will be randomly assigned to one of the three treatment groups.
They will receive monthly intravenous infusions at the clinic for the first three months and apply a skin spray twice daily at home during that period.
The study lasts 12 months total for each participant, with regular visits for blood tests, physical exams, and safety monitoring.
Certain participants in the control groups may switch to the active AdiaVita treatment after three months if they meet safety criteria.
This is a single-blind study, meaning participants will not know which treatment they receive.
Participant safety is closely monitored by the research team and an independent board throughout the study.
Studie Overzicht
Toestand
Werving
Gedetailleerde beschrijving
This study evaluates the safety and preliminary efficacy of a regenerative therapy combined with glutathione in adults with chronic kidney disease.
The primary objective is to determine whether the treatment improves kidney function as measured by estimated glomerular filtration rate and serum creatinine levels.
Secondary objectives focus on assessing safety, tolerability, and the incidence of adverse events.
The study is designed as a randomized, single-blind, controlled trial with three treatment arms.
Participants include approximately 100 adults aged 18 to 80 diagnosed with stage 2-4 chronic kidney disease.
Subjects are recruited through clinical sites, outreach efforts, and partnerships with healthcare providers.
Participants are randomly assigned to receive either the investigational therapy with glutathione, an active control, or a full placebo.
The intervention consists of monthly intravenous infusions over a three-month initial treatment period.
At-home administration of a topical spray is also required during the treatment phase.
A crossover option allows certain participants to receive the investigational therapy after the initial phase if safety criteria are met.
The total study duration per participant is 12 months, including treatment and follow-up.
Data collection includes laboratory assessments, physical exams, and monitoring of adverse events.
Safety oversight is provided through structured monitoring procedures and an independent review board.
Risks include infusion-related reactions, allergic responses, and unknown long-term effects.
Potential benefits include improved kidney function and contributions to scientific knowledge.
All data are securely stored and analyzed, with confidentiality maintained and results reported in a de identified manner.
No monetary incentives are offered, and Patient instead pay a fixed fee of $15,000 for Phase One, which covers all procedures and includes crossover if applicable.
Outcomes will contribute to scientific knowledge regarding the safety and possible clinical utility of stem cell-based therapies for CKD.
Studietype
Ingrijpend
Inschrijving (Geschat)
100
Fase
- Fase 1
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Larry Powalisz
- Telefoonnummer: 3217880850
- E-mail: research@adiamed.com
Studie Locaties
-
-
Florida
-
Winter Park, Florida, Verenigde Staten, 32789
- Werving
- Adia Med Of Winter Park
-
Contact:
- Larry Powalisz
- Telefoonnummer: 3217880850
- E-mail: research@adiamed.com
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- Age 18-80 years
- Confirmed CKD diagnosis (eGFR 15-89 mL/min/1.73 m²)
- Willingness to consider experimental treatments and comply with study requirements
- Ability to obtain required bloodwork
- Ability to attend all scheduled visits
- Able to meet study cost requirements ($15,000 study fee) as described in the informed consent
Exclusion Criteria:
- Has
- Severe allergies to study products
- Significant uncontrolled medical conditions
- Immunocompromised
- Malignancy history
- Unstable medication regimen or inconsistent medication adherence (e.g., frequent medication changes or missed doses) within 30 days prior to Baseline, at Investigator discretion
- Current dialysis (hemodialysis or peritoneal dialysis) or planned initiation of dialysis during the study period
- Pregnancy or breastfeeding (if applicable)
- Participation in another interventional trial within 30 days
- Has had Kidney transplant
- Prior stem cell or glutathione therapy: History of stem cell therapy (including umbilical cord blood-derived stem cells or exosomes) or glutathione therapy (intravenous or topical) at any time prior to screening
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Stem Cell + Glutathione
|
Intraveneuze infusie van cryopreserveerd allogeen product van navelstrengbloed dat levensvatbare mononucleaire cellen (inclusief hematopoëtische en mesenchymale stam-/stromale cellen) en exosomen bevat.
Reduced L-glutathione administered Intravenous infusion once monthly for 3 months (Initial Treatment Schedule)
Transdermal glutathione spray (4 sprays applied twice daily to the skin).
|
|
Actieve vergelijker: Glutathione Control (with Crossover)
|
Reduced L-glutathione administered Intravenous infusion once monthly for 3 months (Initial Treatment Schedule)
Matched placebo intravenous infusion (administered in the same volume and manner as stem cell and exosome product).
Matched placebo transdermal spray (4 sprays applied twice daily).
|
|
Placebo-vergelijker: Placebo Control (with Crossover)
|
Matched placebo intravenous infusion (administered in the same volume and manner as stem cell and exosome product).
Matched placebo transdermal spray (4 sprays applied twice daily).
Matched placebo intravenous infusion administered on the same schedule as active glutathione IV.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
Tijdsspanne: Baseline to Month 6
|
Change from baseline in eGFR (mL/min/1.73
m²)
|
Baseline to Month 6
|
|
Change from Baseline in Serum Creatinine
Tijdsspanne: Baseline to Month 6
|
Change from baseline in serum creatinine level (mg/dL)
|
Baseline to Month 6
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Participants with Treatment-Emergent Adverse Events and Serious Adverse Events
Tijdsspanne: From first infusion through Month 12
|
Number and severity of treatment-emergent adverse events (AEs) and serious adverse events (SAEs) in each treatment arm
|
From first infusion through Month 12
|
|
Change from Crossover Baseline in Estimated Glomerular Filtration Rate (eGFR)
Tijdsspanne: Month 3 to Month 9 (crossover participants only)
|
Change in eGFR from the start of crossover (Month 3) to Month 9 in participants from Arms 2 and 3 who receive AdiaVita
|
Month 3 to Month 9 (crossover participants only)
|
|
Change from Crossover Baseline in Serum Creatinine
Tijdsspanne: Month 3 to Month 9 (crossover participants only)
|
Change in serum creatinine from the start of crossover (Month 3) to Month 9 in participants from Arms 2 and 3 who receive AdiaVita
|
Month 3 to Month 9 (crossover participants only)
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Onderzoekers
- Hoofdonderzoeker: Richard Edwards, DO, Adia Med of Winter Park LLC
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Geschat)
18 mei 2026
Primaire voltooiing (Geschat)
1 januari 2028
Studie voltooiing (Geschat)
1 januari 2029
Studieregistratiedata
Eerst ingediend
1 mei 2026
Eerst ingediend dat voldeed aan de QC-criteria
1 mei 2026
Eerst geplaatst (Werkelijk)
7 mei 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
17 juni 2026
Laatste update ingediend die voldeed aan QC-criteria
16 juni 2026
Laatst geverifieerd
1 juni 2026
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Pathologische processen
- Mannelijke urogenitale ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Chronische ziekte
- Ziekte attributen
- Nierinsufficiëntie
- Pathologische aandoeningen, tekenen en symptomen
- Nier Ziekten
- Nierinsufficiëntie, chronisch
- chromium(IV)-glutathione complex
Andere studie-ID-nummers
- Adia Med CKD Research Study
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Beschrijving IPD-plan
No, we do not plan on sharing IPD data with other researchers.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Ja
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
product vervaardigd in en geëxporteerd uit de V.S.
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .